Edrophonium (cl)

DEA Class;  Rx

Common Brand Names; Enlon

Indicated for myasthenia gravis diagnosis.

For the assessment of cholinesterase inhibitor therapy in patients with myasthenia gravis.

For use to differentiate a myasthenic crisis from a cholinergic crisis (e.g., myasthenic crisis diagnosis).

For use in nondepolarizing neuromuscular blockade reversal.

For the treatment of paroxysmal supraventricular tachycardia (PSVT) or diagnosis of supraventricular arrhythmias

Hypersensitivity

Asthma, Peptic ulcer disease, Hyperthyroidism, Breast-feeding

Edrophonium is contraindicated in GI obstruction or ileus and urinary tract obstruction because cholinergic stimulation of smooth muscle increases the risk of damage to or perforation of these systems.

Seizures 
Bradycardia 
Respiratory arrest 
Cardiac arrest 
Laryngospasm

Dysphagia 
Conjunctival hyperemia
Dysphonia
Dysarthria 
Respiratory depression 
Hypotension

Diarrhea 
Nausea 
Abdominal pain
Hypersalivation 
Miosis 
Lacrimation 
Diplopia 
Diaphoresis 
Dronchial secretions
Weakness 
Increased urinary Frequency

–

The manufacturer warns that the safe use of edrophonium during breast-feeding has not been established. However, the drug’s effect is manifested within 30 to 60 seconds after injection and lasts an average of 10 minutes. Edrophonium is ionized at physiological pH and is therefore not believed to be excreted in breast milk. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. If a breast-feeding infant experiences an adverse effect related to a maternally administered drug, healthcare providers are encouraged to report the adverse effect to the FDA.

AV block, bradycardia, cardiac arrhythmias, cardiac disease, hypotension